Getting to the heart of Lewy body disease
Early identification of neurodegenerative diseases before extensive neuronal loss or disabling symptoms have occurred is imperative for effective use of disease-modifying therapies. Emerging data indicate that central Lewy body diseases — Parkinson disease and dementia with Lewy bodies — can begin in the peripheral nervous system, opening up a therapeutic window before central involvement. In this issue of the JCI, Goldstein et al. report that cardiac 18F-dopamine positron emission tomography reveals lower activity selectively in individuals with several self-reported Parkinson disease risk factors who later develop Parkinson disease or dementia with Lewy bodies. Accurately identifying which at-risk individuals will develop central Lewy body disease will optimize early patient selection for disease-modifying therapies.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Anna E. Goodheart, Craig Blackstone Source Type: research
More News: Biomedical Science | Brain | Cardiology | Dementia | Heart | Neurology | Parkinson's Disease | PET Scan